Novartis: multiple sclerosis drug succeeds in trial
(CercleFinance.com) - Novartis' oral, once-daily siponimod drug for treating secondary progressive multiple sclerosis showed it worked in a phase III study, the Swiss drugmaker said on Friday.
Full results published in The Lancet show significant reductions in the risk of three- and six-month confirmed disability progression with siponimod versus placebo, the company said.
The trial also showed favourable outcomes in other relevant measures of the disease.
Novartis plans to file siponimod for US approval in secondary progressive multiple sclerosis in early 2018. Filing for EU approval is planned for later in 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Full results published in The Lancet show significant reductions in the risk of three- and six-month confirmed disability progression with siponimod versus placebo, the company said.
The trial also showed favourable outcomes in other relevant measures of the disease.
Novartis plans to file siponimod for US approval in secondary progressive multiple sclerosis in early 2018. Filing for EU approval is planned for later in 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.